Termination of a Material Definitive Agreement

MINNEAPOLIS, United States and **BRISBANE, Australia 30 April 2026 (AEST): Anteris Technologies Global Corp.** ("Anteris") (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, announces through its wholly owned subsidiary, Anteris Technologies Corporation (the "Company"), that on April 28, 2026 (April 29, 2026 AEST) it notified v2vmedtech, inc. ("v2v") of its election to discontinue additional development contributions under the Contribution and Stock Purchase Agreement dated April 18, 2023 (the "Agreement").

The Company's election occurred following completion of Stage 1 and during Stage 2 of the development program contemplated by the Agreement.

Pursuant to the Agreement as a result of providing the notice referenced above:

- The Company is required to pay a break fee of US $400,000 to v2v, which will be used by v2v for continued development of the technology.
- The Company has no further obligation to make additional development contributions under the Agreement.
- The initial shareholders of v2v have the right, at their election, to either:
  - acquire all of the Company's equity interest in v2v for an amount equal to the Company's aggregate contributions to date, or
  - reduce the Company's equity interest in v2v to a capped minority ownership percentage as specified in the Agreement.

v2v has not informed the Company as to which option it intends to pursue.

In addition, as a result of the termination of the Company's obligation to make further development contributions to v2v under the Agreement, the Development Agreement by and between the Company, dated as April 18, 2023 (the "Development Agreement"), will terminate upon the payment of the US $400,000 break fee.

The Company does not expect the discontinuation of contributions under the Agreement and the termination of the Development Agreement to have a material adverse effect on its consolidated financial position or liquidity.

ENDS

About Anteris

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.

Anteris' lead product, the DurAVR® Transcatheter Heart Valve ("THV"), was designed in collaboration with the world's leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR® THV is made using a single piece of molded ADAPT® tissue, Anteris' patented anti-calcification tissue technology. ADAPT® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR® THV System is comprised of the DurAVR® valve, the ADAPT® tissue, and the balloon-expandable ComASUR® Delivery System.

Forward-Looking Statements

This announcement contains forward-looking statements, including those regarding v2v's expected use of the break fee, the initial shareholders of v2v's election options, and the expected impact of the discontinuation of contributions on Anteris' consolidated financial position or liquidity. Forward-looking statements include all statements that are not historical facts. Forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "budget," "target," "aim," "strategy," "plan," "guidance," "outlook," "may," "should," "could," "will," "would," "will be," "will continue," "will likely result" and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described under "Risk Factors" in Anteris' Annual Report on Form 10-K for the fiscal period ended December 31, 2025 that was filed with the Securities and Exchange Commission and ASX. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, Anteris does not assume any obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations.

Authorisation and Additional information

This announcement was authorised for release on the ASX by the Chief Executive Officer.

For more information:

Investor Relations
investors@anteristech.com
Debbie Ormsby
Anteris Technologies Global Corp.
+61 1300 550 310 | +61 7 3152 3200

Investor Relations (US)
mchatterjee@bplifescience.com
Malini Chatterjee, Ph.D.
Blueprint Life Science Group
+1 917 330 4269

Website	www.anteristech.com
X	@AnterisTech
LinkedIn	https://www.linkedin.com/company/anteristech